CoChat
Sign Up
Cited by 98Multiple Sclerosis Research StudiesGlaucoma and retinal disordersOcular Diseases and Behçet’s Syndrome

Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning

Open access
Sotirchos, Elias S, Filippatou, Angeliki, Fitzgerald, Kathryn C, Salama, Sara, Pardo, Santiago, Wang, Jiangxia, Ogbuokiri, Esther, Cowley, Norah J +7 more·2020·Multiple Sclerosis Journal
DOI 10.1177/1352458519864928PMC PMC6992495
Open this paper in CoChat — free account

Abstract

Background: Comparative studies of characteristics of optic neuritis (ON) associated with myelin oligodendrocyte glycoprotein-IgG (MOG-ON) and aquaporin-4-IgG (AQP4-ON) seropositivity are limited. Objective: To compare visual and optical coherence tomography (OCT) measures following AQP4-ON, MOG-ON, and multiple sclerosis associated ON (MS-ON). Methods: In this cross-sectional study, 48 AQP4-ON, 16 MOG-ON, 40 MS-ON, and 31 healthy control participants underwent monocular letter-acuity assessment and spectral-domain OCT. Eyes with a history of ON >3 months prior to evaluation were analyzed. Results: AQP4-ON eyes exhibited worse high-contrast letter acuity (HCLA) compared to MOG-ON (−22.3 ± 3.9 letters; p < 0.001) and MS-ON eyes (−21.7 ± 4.0 letters; p < 0.001). Macular ganglion cell + inner plexiform layer (GCIPL) thickness was lower, as compared to MS-ON, in AQP4-ON (−9.1 ± 2.0 µm; p < 0.001) and MOG-ON (−7.6 ± 2.2 µm; p = 0.001) eyes. Lower GCIPL thickness was associated with worse HCLA in AQP4-ON (−16.5 ± 1.5 letters per 10 µm decrease; p < 0.001) and MS-ON eyes (−8.5 ± 2.3 letters per 10 µm decrease; p < 0.001), but not in MOG-ON eyes (−5.2 ± 3.8 letters per 10 µm decrease; p = 0.17), and these relationships differed between the AQP4-ON and other ON groups ( p < 0.01 for interaction). Conclusion: AQP4-IgG seropositivity is associated with worse visual outcomes after ON compared with MOG-ON and MS-ON, even with similar severity of macular GCIPL thinning.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1352458519864928

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. [1]Wingerchuk DM, Hogancamp WF, O’Brien PC, The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107– 14. 10496275
  2. [2]Merle H, Olindo S, Bonnan M, Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114: 810– 5. 17141316
  3. [3]Lennon VA, Kryzer TJ, Pittock SJ, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473– 7. 16087714 PMC2212860
  4. [4]Kitley J, Waters P, Woodhall M, Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276– 283. 24425068
  5. [6]Chen JJ, Flanagan EP, Jitprapaikulsan J, Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol 2018; 195: 8– 15. 30055153 PMC6371779
  6. [7]Bennett JL, de Seze J, Lana-Peixoto M, Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler 2015; 21: 678– 688. 25662342 PMC4425816
  7. [8]Gelfand JM, Nolan R, Schwartz DM, Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012; 135: 1786– 93. 22539259 PMC3359753
  8. [9]Saidha S, Sotirchos ES, Ibrahim MA, Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11: 963– 972. 23041237 PMC3533139
  9. [10]Sotirchos ES, Saidha S, Byraiah G, In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 2013; 80: 1406– 1414. 23516321 PMC3662269
  10. [11]Kaufhold F, Zimmermann H, Schneider E, Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS ONE 2013; 8: e71145. 23940706 PMC3735514
  11. [12]Gelfand JM, Cree BA, Nolan R, Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol 2013; 70: 629– 633. 23529376
  12. [13]Hokari M, Yokoseki A, Arakawa M, Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol 2016; 79: 605– 624. 26836302
  13. [14]Pache F, Zimmermann H, Mikolajczak J, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016; 13: 282. 27802824 PMC5088645
  14. [15]Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord 2016; 9: 436– 440. 27582898 PMC4994783
  15. [16]Havla J, Kümpfel T, Schinner R, Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 2017; 264: 139– 151. 27844165
  16. [17]Stiebel-Kalish H, Lotan I, Brody J, Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. PLoS ONE 2017; 12: e0170847. 28125740 PMC5268377
  17. [18]Zhao G, Chen Q, Huang Y, Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol 2018; 265: 33– 40. 29101456
  18. [19]Waters P, Woodhall M, O’Connor KC, MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015; 2: e89. 25821844 PMC4370386
  19. [20]Reindl M and Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2018. 30559466
  20. [22]Syc SB, Warner CV, Hiremath GS, Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 2010; 16: 829– 839. 20530512
  21. [23]Tewarie P, Balk L, Costello F, The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment. PLOS ONE 2012; 7: e34823. 22536333 PMC3334941
  22. [24]Lang A, Carass A, Hauser M, Retinal layer segmentation of macular OCT images using boundary classification. Biomed Opt Express 2013; 4: 1133– 1152. 23847738 PMC3704094
  23. [25]Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 2016; 86: 2303– 2309. 27225223 PMC4909557
  24. [26]Bender R and Lange S. Adjusting for multiple testing--when and how?. J Clin Epidemiol 2001; 54: 343– 9. 11297884
  25. [27]Weber MS, Derfuss T, Metz I, Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord 2018; 11. PMC5881972 29623106
  26. [28]Pannicke T, Wurm A, Iandiev I, Deletion of aquaporin-4 renders retinal glial cells more susceptible to osmotic stress. J Neurosci Res 2010; 88: 2877– 88. 20544823
  27. [29]Shen W, Fruttiger M, Zhu L, Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. J Neurosci 2012; 32: 15715– 15727. 23136411 PMC4014009
  28. [30]Oertel FC, Kuchling J, Zimmermann H, Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017; 4: e334. 28255575 PMC5322864
  29. [31]Green AJ and Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatr 2009; 80: 1002– 5. 19465415
  30. [32]Lucchinetti CF, Mandler RN, McGavern D, A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125: 1450– 61. 12076996 PMC5444467
  31. [33]Naismith RT, Tutlam NT, Xu J, Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72: 1077– 82. 19307541 PMC2677471
  32. [34]FitzGibbon T and Nestorovski Z. Morphological consequences of myelination in the human retina. Exp Eye Res 1997; 65: 809– 819. 9441705
  33. [35]Ogden TE. Nerve fiber layer of the primate retina: thickness and glial content. Vision Res 1983; 23: 581– 587. 6612997
  34. [36]Silverman SM and Wong WT. Microglia in the Retina: Roles in Development, Maturity, and Disease. Annu Rev Vis Sci 2018; 4: 45– 77. 29852094
  35. [37]Pittock SJ, Lennon VA, Bakshi N, Seroprevalence of Aquaporin-4–IgG in a Northern California Population Representative Cohort of Multiple Sclerosis. JAMA Neurol 2014; 71: 1433– 1436. 25178362
  36. [38]Syc SB, Saidha S, Newsome SD, Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012; 135: 521– 33. 22006982 PMC3281477
  37. [39]Beck RW, Cleary PA and Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994; 101: 1771– 1778. 7800355

Cited by

Sorted by citations

Authors
Sotirchos, E. S., Filippatou, A., Fitzgerald, K. C., Salama, S., Pardo, S., Wang, J., Ogbuokiri, E., Cowley, N. J., Pellegrini, N., Murphy, O. C., Mealy, M. A., Prince, J. L., Levy, M., Calabresi, P. A., & Saidha, S.
Affiliations
Johns Hopkins University (US)
Corresponding author
Sotirchos, Elias S
ORCID
Venue
Multiple Sclerosis Journal
Publisher
SAGE Publications
Published
2019-07-31
Volume
26
Issue
11
Pages
1360-1371
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
DOI
10.1177/1352458519864928
PMC
PMC6992495
OpenAlex
W2964450401
Cited by
98
References
2
Citations by year
2026: 7 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 18 · 2021: 17 · 2020: 16 · 2019: 2
FWCI
9.75
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Multiple Sclerosis Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Multiple Sclerosis Society (FP-1607-24999, RG-1606-08768)
  • National Institutes of Health (4K08NS078555, 5R01NS082347)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
optic neuritis, multiple sclerosis, visual outcome, letter acuity, macular ganglion cell layer thickness, inner plexiform layer, optical coherence tomography, visual prognosis, macular atrophy
MeSH terms
Autoantibodies, Cross-Sectional Studies, Humans, Immunoglobulin G, Multiple Sclerosis, Optic Neuritis, Visual Acuity, Tomography, Optical Coherence, Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review